Wells Fargo lowered the firm’s price target on Sutro Biopharma (STRO) to $3 from $4 and keeps an Equal Weight rating on the shares. The firm remains on the sidelines given the early nature of Sutro’s clinical pipeline as management works to get its multiple ADC programs into the clinic. Shares are likely to remain range bound, Wells adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO:
- Sutro Biopharma’s Strategic Shift and Pipeline Developments: A Hold Rating Amid Transitional Phase
- Sutro Biopharma Advances ADC Pipeline and Reports Q2 2025 Results
- Sutro Biopharma enters research collaboration with FDA for ADC standards
- Sutro Biopharma Faces NASDAQ Non-Compliance Notice
- Sutro, Sarepta, Incyte, Signet, Wix: Trending by Analysts